Efficient T-cell engineering is crucial for the success of CAR T-cell therapy research, but it requires multiple labor-intensive steps, including T-cell isolation, activation, and transduction.

In an analysis of therapeutic interventions following the failure of chimeric antigen receptor (CAR) T-cell therapy, Rahul ...

What major challenge of traditional CAR-T does the in vivo alleviate/address? In addi | Dr Adrian Bot, Capstan Therapeutics, ...

Crystalline polymers assembled inside tumor cell lysosomes rupture membranes, release iron, and trigger immune-activating ...

Scientists in Brazil are refining the design of CAR-engineered immune cells to make them more precise and powerful against cancer.

Cancer immunotherapy transforms a patient’s immune cells into a “search‑and‑destroy” force against tumors. But many cancers learn to camouflage themselves from dendritic cells—the immune system’s ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

Ziftomenib in relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study. This is an ASCO Meeting Abstract ...

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...